In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Leukemia

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.leu.2403253PMID 14712291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.

  2002cited by this paper
• Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance

  2002cited by this paper
• The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.

  2000cited by this paper
• Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.

  2000cited by this paper
• Biological and therapeutic aspects of infant leukemia.

  2000cited by this paper
• Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.

  1999cited by this paper
• Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

  1999cited by this paper
• Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.

  1999cited by this paper
• Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) – a report of the Children’s Cancer Group

  1999cited by this paper
• Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set

  1999cited by this paper
• Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay

  1999cited by this paper
• Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis

  1998cited by this paper
• Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.

  1998cited by this paper
• Mechanisms of cellular anthracycline resistance in childhood acute leukemia

  1998cited by this paper
• Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89.

  1998cited by this paper
• Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants

  1998cited by this paper
• Intensified therapy for infants with acute lymphoblastic leukemia

  1997cited by this paper
• Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia

  1997cited by this paper
• Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse.

  1997cited by this paper
• In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.

  1997cited by this paper
• In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.

  1997cited by this paper
• In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia

  1997cited by this paper
• Infant leukaemia biology, aetiology and treatment.

  1996cited by this paper
• Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome.

  1996cited by this paper
• 11q23 rearrangements in acute leukemia.

  1996cited by this paper
• Translocation (11;15)(q23;q14) in three patients with acute non-lymphoblastic leukemia (ANLL): clinical, cytogenetic and molecular studies.

  1995cited by this paper
• Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis.

  1995cited by this paper
• Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).

  1995cited by this paper
• The drug resistance-related protein LRP is the human major vault protein

  1995cited by this paper
• The role of immunophenotype in acute lymphoblastic leukemia of infant age.

  1994cited by this paper
• Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study.

  1994cited by this paper
• Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.

  1994cited by this paper
• Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay.

  1994cited by this paper
• Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

  1993cited by this paper
• Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

  1991cited by this paper
• In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood.

  1991cited by this paper
• Detection of the Philadelphia chromosome in interphase nuclei.

  1990cited by this paper
• In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

  1990cited by this paper
• In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions

  1990cited by this paper
• Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia.

  1988cited by this paper
• Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

  1977cited by this paper

• Application of Omics Analyses in Pediatric B-Cell Acute Lymphoblastic Leukemia

  2025cites this paper
• Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

  2025cites this paper
• Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

  2025cites this paper
• Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions

  2024cites this paper
• Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia

  2024cites this paper
• Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells

  2023cites this paper
• Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia

  2023cites this paper
• Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

  2023cites this paper
• Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

  2022cites this paper
• Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia

  2022cites this paper
• Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia

  2021cites this paper
• Genetic Alterations in Childhood Acute Lymphoblastic Leukemia: Interactions with Clinical Features and Treatment Response

  2021cites this paper
• Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival

  2021cites this paper
• Therapeutic implications of menin inhibition in acute leukemias

  2021cites this paper
• Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A-rearranged leukemia

  2021cites this paper
• A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program

  2021cites this paper
• Single cell mRNA signals reveal a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia

  2021cites this paper
• Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

  2020cites this paper
• Single-cell multi-omics reveals elevated plasticity and stem-cell-like blasts relevant to the poor prognosis of KMT2A-rearranged leukemia

  2020cites this paper
• MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.

  2020cites this paper
• MLL-Rearranged Acute Lymphoblastic Leukemia

  2020cites this paper
• Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.

  2020cites this paper
• Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Determinants of clinical outcome in MLL-rearranged infant acute lymphoblastic leukemia : Determinanten van klinische uitkomst bij zuigelingen met acute lymfatische leukemie met een MLL-herschikking

  2019cites this paper
• Mutagenic players in ALL progression and their associated signaling pathways.

  2019cites this paper
• Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.

  2019cites this paper
• Современные представления о терапии острого лейкоза у детей до 1 года

  2019cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Pediatric Acute Lymphoblastic Leukemia, Version 2.2020

  2019cites this paper
• How I treat infant leukemia.

  2019cites this paper
• Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib

  2019cites this paper
• Modern views on the treatment of acute leukemia in children under 1 year

  2019cites this paper
• Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL

  2018cites this paper
• Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia

  2018cites this paper
• Cesarean Delivery and Risk of Infant Leukemia: A Report from the Children's Oncology Group

  2018cites this paper
• How I Treat How I treat infant leukemia

  2018cites this paper
• MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches

  2017cites this paper
• Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice

  2016cites this paper
• Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias

  2016cites this paper
• POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL

  2015cites this paper
• Overexpression of EPS8 is associated with poor prognosis in patients with acute lymphoblastic leukemia.

  2015cites this paper
• The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.

  2015cites this paper
• Effective Targeting of the P 53 – MDM 2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

  2015cites this paper
• Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

  2015cites this paper
• Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition

  2014cites this paper
• Childhood B-acute lymphoblastic leukemia: a genetic update

  2014cites this paper
• Unraveling Glucocorticoid Resistance In MLLrearranged Infant Acute Lymphoblastic Leukemia

  2014cites this paper
• Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL

  2014cites this paper
• Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells

  2013cites this paper
• Importance of Detecting Multidrug Resistance Proteins in Acute Leukemia Prognosis and Therapy

  2013cites this paper
• Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants

  2013cites this paper
• Treatment of infant leukemias: challenge and promise.

  2013cites this paper
• MLL‐rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism

  2013cites this paper
• Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia

  2013cites this paper
• Diagnostics of Molecular Markers in Childhood Acute Leukaemia Using Biochips

  2011cites this paper
• Multidrug Resistance Mechanism of Acute Lymphoblastic Leukemia

  2011cites this paper
• Infant Acute Lymphoblastic Leukemia Rob Pieters

  2010cites this paper
• Biology and treatment of acute lymphoblastic leukemia.

  2010cites this paper
• Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.

  2010cites this paper
• Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

  2010cites this paper
• Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia

  2010cites this paper
• Infant acute lymphoblastic leukemia: Lessons learned and future directions

  2009cites this paper
• Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan infant leukemia study group

  2009cites this paper
• High-risk childhood acute lymphoblastic leukemia.

  2009cites this paper
• Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase

  2009cites this paper
• Optimizing chemotherapy in childhood acute myeloid leukemia.

  2008cites this paper
• Reduced Expression and Defective Modulation of TNF Receptor/Ligand Family Molecules on proB-ALL Blasts

  2008cites this paper
• Chapter 27 – Molecular Genetics of ALL

  2008cites this paper
• METHOD FOR TREATMENT OF CANCERS OR INFLAMMATORY DISEASES HELD OF THE INVENTION This invention relates to the use of a glycosylasparaginase polypeptide with L- asparaginase activity or its precursor in the treatment or prevention of cancers

  2008cites this paper
• Biology and treatment of acute lymphoblastic leukemia.

  2008cites this paper
• Acute lymphoblastic leukemia in infancy

  2007cites this paper
• Utilidad del inmunofenotipo en el diagnóstico y el seguimiento de la leucemia linfoblástica aguda del adulto

  2007cites this paper
• Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.

  2007cites this paper
• Treatment of MLL gene rearranged Acute Lymphoblastic Leukemia

  2006cites this paper
• A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia

  2006cites this paper
• Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia.

  2006cites this paper
• Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia

  2006cites this paper
• MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia

  2006cites this paper
• The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.

  2006cites this paper
• Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.

  2006cites this paper
• Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells

  2006cites this paper
• Novel genomic determinants of apoptotic defects in acute lymphoblastic leukemia

  2006cites this paper
• Molecular Insights in MLL Rearranged Acute Leukemia

  2006cites this paper
• Towards targeted therapy for infant acute lymphoblastic leukaemia

  2006cites this paper
• Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner

  2006cites this paper
• Infant leukaemia: clinical, biological and therapeutic advances.

  2006cites this paper
• Infant leukaemia: Clinical, biological and therapeutic advances

  2006cites this paper
• FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.

  2005cites this paper
• 1 Targeting FLT 3 in primary MLL gene rearranged infant acute lymphoblastic leukemia

  2005cites this paper
• Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

  2005cites this paper
• Multidrug resistance and minimal residual disease in childhood malignancies

  2005cites this paper
• The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescence

  2005cites this paper
• Cellular drug sensitivity in MLL‐rearranged childhood acute leukaemia is correlated to partner genes and cell lineage

  2005influential citation